Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder

Purpose of Review Patients with bipolar disorder are frequently treated with polypharmacy. This article should provide clinicians with an understanding of how polypharmacy can contribute to pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs). Recent Findings The pharmacokinetics and ph...

Full description

Saved in:
Bibliographic Details
Published in:Current psychiatry reports 2018-03, Vol.20 (3), p.17-17, Article 17
Main Authors: de Leon, Jose, Spina, Edoardo
Format: Article
Language:English
Subjects:
Adult
Antidepressants
Antimanic Agents - pharmacology
Antimanic Agents - therapeutic use
Antipsychotic Agents - pharmacology
Antipsychotic Agents - therapeutic use
Bipolar disorder
Bipolar Disorder - drug therapy
Drug Interactions
Humans
Lithium Compounds - pharmacology
Lithium Compounds - therapeutic use
Medicine
Medicine & Public Health
Mood Disorders (E Baca-Garcia
Pharmacodynamics
Pharmacokinetics
Polypharmacy
Psychiatry
Section Editor
Serotonin Uptake Inhibitors - pharmacology
Serotonin Uptake Inhibitors - therapeutic use
Topical Collection on Mood Disorders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review Patients with bipolar disorder are frequently treated with polypharmacy. This article should provide clinicians with an understanding of how polypharmacy can contribute to pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs). Recent Findings The pharmacokinetics and pharmacodynamics of lithium and other mood stabilizers (valproate, lamotrigine, carbamazepine, oxcarbazepine, and eslicarbazepine), antipsychotics, and selective serotonin reuptake inhibitors (SSRIs) were reviewed and summarized in the first four tables describing their pharmacokinetic and pharmacodynamic mechanisms. Summary Four tables summarized the DDIs which are likely to be clinically relevant in adults with bipolar disorder: two for mania treatments (with and without carbamazepine), one for maintenance treatments, and one for depression treatments. The purpose is to be practical, helping clinicians pay attention to and manage polypharmacy, avoiding adverse drug reactions (ADRs) in patients with bipolar disorder, including both the frequent ADRs and those rare but potentially lethal ADRs. Future articles should improve these tables.
ISSN:1523-3812
1535-1645
DOI:10.1007/s11920-018-0881-3